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Abstract
Background. The level at which low-level lead exposure produces subclinical adverse health effects in adults remains to be 
established. Methods. The Study for Promotion of Health in Recycling Lead (SPHERL) will enroll 500 newly hired work-
ers, whose blood lead during 2 years of follow-up is expected to increase from levels less than 2 mg/dl, as currently observed 
in the US population, to 20–30 mg/dl. The main outcome variables to be studied are (i) blood pressure (BP) analyzed as 
a continuous or categorical variable, both cross-sectionally and longitudinally, and using conventional and ambulatory BP 
measurement; (ii) indexes of glomerular and tubular renal function, (iii) heart rate variability analyzed in the frequency 
domain as measure of autonomous sympathetic modulation, (iv) peripheral nerve conductivity velocity, (v) neurocognitive 
performance, and (vi) quality of life. Expected outcomes. Assuming a 10-fold increase in blood lead, SPHERL will have suf-
ficient statistical power to detect over 2 years a steepening of the age-related rise in systolic BP from 1 to 5 mmHg and a 
doubling of the age-related decline in the estimated glomerular filtration rate from 3.5 to 7.0 ml/min/1.73 m2. The longi-
tudinal design of our study complies with the temporality principle of the Bradford–Hill criteria for assessing possible 
causality between outcomes and exposure. SPHERL will attempt to resolve the apparent contradiction between general 
population studies showing associations between adverse health effects and low lead exposure with blood lead levels below 
5 mg/dl and studies conducted in occupational cohorts indicating that adverse effects of lead exposure occur at much higher 
blood lead levels.
Key Words: Autonomic nervous function, blood pressure, cardiovascular regulation, lead, occupational exposure, renal function
Introduction
High-level lead exposure causes hypertension and 
renal dysfunction (1,2). However, there is no general 
agreement as to whether low-level lead exposure 
increases blood pressure (BP) or affects renal func-
tion. in a meta-analysis of 58 518 subjects (1), 
recruited from the general population in 119 surveys 
and from occupationally exposed groups in 12 stud-
ies, a twofold increase in blood lead concentration 
was associated with a 1.0-mmHg increase in systolic 
BP (Figure 1) and a 0.6-mmHg increase in diastolic 
BP. in a population study of renal function, blood 
lead ranged from 1.7 to 60.3 mg/dl (geometric 
mean  7.5 mg/dl) in women and from 2.3 to 72.5 
mg/dl (mean  11.4 mg/dl) in men (2). in both 
women and men (Table i), creatinine clearance was 
inversely correlated with blood lead, suggesting that 
low-level lead exposure may impair renal function 
(2). However, because of the cross-sectional design, 
the alternative hypothesis that renal impairment may 
increase the blood lead concentration could not be 
excluded (2).
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Figure 1. Change in the systolic pressure (association size in mmHg with 95% confidence interval) associated with a doubling of the blood 
lead concentration. Circles represent individual groups and squares the combined association size. open circles denote groups for whom 
a non-significant systolic association size was assumed to be zero. C, Caerphilly Study; HP, Welsh Heart Program; W, Whites; B, Blacks; 
Ni, Non-immigrants; i, immigrants; FW, Foundry Workers; CS, Civil Servants; P, PheeCad (Public Health and Environmental Exposure 
to Cadmium) Study. Reproduced with permission from ref. (1).
Table i. Determinants of the measured creatinine clearance rate.
Relation with blood lead Relation with zinc protoporphyrin
Variable Women (n  1016) Men (n  965) Women (n  1016) Men (n  965)
R2 0.25 0.27 0.25 0.26
intercept 99 86 79 66
Partial regression coefficient
Log lead (mg/l) –12.64*** –9.51** – –
Log zinc protoporphyrin (mg/g hemoglobin) – – –7.72* –8.88**
Age (years)  0.05†  0.71***  0.22†  0.43†
Age squared (years2)  0.006***  0.015***  0.005***  0.012***
Body mass index (kg/m2)  0.92***  1.76***  0.99***  1.72***
Log g-glutamyltransferase (units/l) NS –6.38** NS NS
Diuretic therapy (0,1) –7.56*** –8.77** –8.04*** –8.48**
 The creatinine clearance averaged (SD) 80 (25) ml/min in women and 99 (30) in men. The variables considered for entry in the multiple 
regression model were the linear and squared terms of age, body mass index, mean blood pressure, blood and 24-h urinary cadmium, 
serum ferritin, a history of diabetes mellitus, smoking, g-glutamyltransferase (index of alcohol intake), use of analgesic and diuretic drugs, 
exposure to heavy metals at work, and residence in a rural vs. urban area. The linear and squared terms of age were tested simultaneously 
for entry into the regression model. Significance of the partial regression coefficients: *p  0.08; **p  0.05; ***p  0.001. NS and †denote 
non-significant. Reproduced with permission from ref. (2).
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 Rationale and design of SPHERL  149
Following the studies referenced above (1,2), 
other investigators have published a number of epi-
demiological (3–15) and experimental (16,17) stud-
ies that described associations between lead exposure 
and adverse effects upon BP (3–6), cardiovascular 
(7,8,16) or renal (9–14,17) function outcomes, or on 
the autonomic nervous system (15). Most, albeit not 
all (4–6,8,13,14), of these epidemiological studies 
had a cross-sectional design (3,7,9–12,15). Agencies, 
such as the European Food Safety Authority (EFSA) 
(18), the National Toxicology Program (19) and the 
Environmental Protection Agency (EPA) in the USA 
(20,21), considered these studies in weight-of- 
the-evidence analyses (22), which suggested that 
blood lead levels as low as 5 mg/dl might be associ-
ated with adverse effects. However, the ensuing con-
sensus documents (18,20,21,23) based on general 
population epidemiological data are in apparent con-
flict with the scientific literature on the effects of lead 
exposure in workers, which suggest that effects on 
the cardiovascular, renal and autonomous nervous 
systems occur at much higher blood lead levels. The 
explanations commonly put forward for the apparent 
contradiction between general population epidemio-
logical and occupational studies are higher statistical 
power in large epidemiological populations relative 
to smaller occupational cohorts and selection bias, 
often referred to as the healthy worker effect (24). 
However, other variables, such as uncertainties in the 
lead exposure history, unaddressed confounders, 
insufficient quality control for evaluation of the phe-
notype of interest, and the timing of lead exposure 
relative to onset of associated effects have not yet 
been satisfactorily addressed. The Study for Promo-
tion of Health in Recycling Lead (SPHERL) will 
address the aforementioned issues in a longitudinal 
study of workers whose blood lead levels will rise from 
general population to occupational exposure levels.
Design and research objectives
SPHERL is a prospective 2-year follow-up study of 
lead workers with exposure levels varying between 
and within individuals. SPHERL will address the 
extent to which between-subject differences or with-
in-subject changes in lead exposure may have a mea-
surable impact on BP, the cardiovascular system, 
renal function, the autonomic nervous system, 
peripheral nerve conduction velocity, neurocognitive 
function and quality of life. The longitudinal design 
of SPHERL complies with the Bradford–Hill criteria 
(25) to assess possible causality between adverse 
health outcomes and exposure to a toxic substance.
General design
The medical and nursing staff of lead recycling and 
battery manufacturing plants in North America will 
enroll and organize a 2-year follow-up of workers in 
two strata: (i) new hires without previous occupa-
tional lead exposure who will be performing tasks 
with lead exposure or current employees without 
previous occupational lead exposure, who anticipate 
moving to jobs with lead exposure; and (ii) new hires 
without previous occupational lead exposure who do 
not anticipate performing tasks with lead exposure 
within 2 years. The projected increase in blood lead 
in stratum 1 is from levels currently observed in the 
US population, 1.51 mg/dl in NHANES iV (3), to 
20–30 mg/dl. Workers in stratum 2 will experience a 
minimal increase in exposure, share the same living 
environment as the exposed workers, and might serve 
as a control group in sensitivity analyses using a 
nested-case-control design. The possibility of selec-
tion bias needs to be considered when generalizing 
findings because some of the eligible subjects may 
not participate in this survey. The medical services at 
the plants will keep a log of workers invited to take 
part in SPHERL. The information to be recorded for 
non-participants will consist of ethnicity, sex, age, 
height and weight, and the main reason for declining 
participation. These data will serve to compute the 
participation rate among invitees and to assess the 
generalizability of the SPHERL findings by compar-
ing non-participants with participants.
The Studies Coordination Centre in Leuven, Bel-
gium, will function as coordinating office for 
SPHERL and be responsible for database construc-
tion, statistical analysis and drafting scientific reports. 
SPHERL complies with the Declaration of Helsinki 
for studies in human volunteers (26). All participants 
will provide informed written consent. The institu-
tional Review Board overseeing biomedical research 
at the University of Leuven approved the study pro-
tocol. The Studies Coordination Centre complies 
with the Belgian legislation on the protection of pri-
vate information (http://www.privacycommission.
be/). The databases managed at the Studies Coordi-
nating Centre are registered with the Privacy Com-
mission (Brussels, Belgium). its members are experts 
in the protection of privacy and of personal data and 
apply standards that are internationally agreed upon 
(http://www.privacycommission.be/sites/ privacy-
commission/files/documents/international_stan-
dards_madrid_2009.pdf).
Primary and secondary outcomes
Longitudinal outcomes in individual participants. The 
primary endpoint of SPHERL is the annual change 
in systolic BP, as measured by 24-h ambulatory mon-
itoring, associated with changes in the blood lead 
concentration from occupational lead exposure. BP 
related secondary endpoints will be evaluated in the 
longitudinal analyses and will include changes in the 
conventionally measured office BP and the incidence 
of hypertension on ambulatory monitoring or office 
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measurement. other secondary endpoints are 
changes in: (i) the central hemodynamics, including 
aortic BP, the central systolic augmentation index 
and aortic pulse wave velocity; (ii) ECG-derived 
indexes; (iii) glomerular and tubular renal function 
measured on a continuous scale; (iv) the incidence 
of renal dysfunction; (v) alterations in the autonomic 
nervous cardiovascular modulation, as assessed by 
heart rate variability; (vi) nerve conduction velocity; 
(vii) neurocognitive function; and (viii) self-assessed 
quality of life.
Cross-sectional analyses. As the study progresses, 
cross-sectional analyses based on data accrued annu-
ally will form the basis for interim reports and 
quality assurance.
Sample size. With two-sided significance set at 5% 
and power set at 90%, approximately 260 partici-
pants must be followed up for 2 years to demonstrate 
a significant increase in the 24-h systolic BP and a 
significant decline of the estimated glomerular filtra-
tion rate (eGFR) with increasing blood lead over a 
2-year follow-up. Because the anticipated attrition 
rate over 2 years is projected to be as high as 50%, 
approximately 500 participants must be enrolled. 
Previous observations in our population studies (2,6) 
informed these sample size calculations. For BP (6), 
we assumed that (i) a 10-fold increase in the blood 
lead concentration will steepen the age-related rise 
in BP over 2 years from 1 to 5 mmHg systolic, and 
that (ii) the SDs for of the within-subject changes are 
10 mmHg for systolic BP and 0.5 for the logarithmi-
cally transformed blood lead concentration. The 
decrease in eGFR with aging 2 years was estimated 
from the regression coefficients shown in Table i. For 
eGFR (2), we additionally assumed that a 10-fold 
increase in blood concentration will double the 2-year 
age-related decrease in eGFR from 3.5 to 7.0 ml/
min/1.73 m2 with a within-subject SD of the changes 
equal to 10 ml/min/1.73 m2. eGFR will be primarily 
derived from cystatin C (27), but for reasons of com-
parability with the existing literature, creatinine-
based methods will also be used (28,29). Compared 
with serum creatinine, cystatin C levels are less 
dependent on ethnicity, sex, age and muscle mass or 
protein intake, and eGFR based on cystatin C is 
superior to creatinine-based methods in assessing 
serial changes in eGFR (30).
Procedures and measurements
The study involves a physical examination, adminis-
tration of questionnaires, measurement of BP, car-
diovascular and renal function, autonomic nervous 
tone, peripheral nerve conduction velocity and neu-
rocognitive performance, and tests on blood and 
fresh urine samples. Before examination at baseline 
and at the two annual follow-up visits, the workers 
will refrain from smoking, drinking alcohol or caf-
feinated beverages and heavy physical activity for at 
least 3 h.
Physical examination
Trained nurses will measure body weight and height, 
waist and hip circumference, skinfolds and body 
composition. A tape measure will be used to deter-
mine the waist and hip circumferences. The umbi-
licus and greater trochanter will be the landmarks 
for measuring waist and hip circumference. Skin-
folds will be measured at the left side of the workers’ 
body, using a caliper providing a constant pressure 
of 0.01 kg/mm2 (0.098 N/mm2) 10% at all open-
ings of the 90-mm2 anvils (Harpenden caliper, Baty 
international, Burgess Hill, West Sussex, UK). The 
subscapular, triceps and anterior suprailiac skinfolds 
will be determined at the inferior angle of the scap-
ula, the mid portion of the triceps, and just above 
the spina iliaca anterior superior, respectively. For 
measurement of body composition, the nurses will 
use the Bodystat® QuadScan 4000 (Bodystat Ltd., 
isle of Man, UK). This device applies scientifically 
validated principles of bio-electrical impedance 
(31) and provides detailed information on a large 
number of variables, including lean and fat free 
mass, body fat mass index, fat free mass index, and 
the distribution of total body water over the intra- 
and extra-cellular space (http://www.bodystat.ca/
QSeries/Product3-Details/QuadScan-4000.aspx).
Questionnaires
We will use a standardized and validated question-
naire, inquiring about each worker’s medical history, 
occupations, exposure to heavy metals, smoking and 
drinking habits, intake of medications and lifestyle. 
The energy spent in physical activity will be calcu-
lated from the time devoted to sports and physical 
labor with use of published tables. The questionnaire 
also provides information on the menstrual status of 
women. The EQ-5D questionnaire will be the instru-
ment to assess quality of life. The EQ-5D allows gen-
erating utilities, and consequently quality-adjusted 
life years (QALYs) in relation to the level of lead 
exposure. Several articles (32) describe the develop-
ment of statistical models for generating population-
based EQ-5D preference weights specific for the 
USA.
Assessment of the cardiovascular system
Office BP. Current guidelines (33) and a stringent 
quality control program (34) will be applied to record 
the office and 24-h ambulatory BP. At the enrolment 
visit, nurses will measure upper arm circumference. 
Standard cuffs have a 12  24 cm inflatable portion, 
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but if upper arm girth exceeds 31 cm, larger cuffs 
with 15  35 cm bladders should be used. BP mea-
surements will be obtained at the non-dominant 
arm, unless at recruitment the difference in systolic 
or diastolic BP between both arms is 10 mmHg or 
more. in this case, the cuffs for office and ambulatory 
BP measurement will be applied to the arm giving 
the highest BP level. After the workers have rested 
for 5 min in the sitting position, the nurses will obtain 
five consecutive BP readings to the nearest 2 mmHg, 
using standard mercury sphygmomanometers. Next, 
they will obtain two consecutive readings immedi-
ately after the participants assumed the standing 
position. For analysis, the five sitting and two stand-
ing readings will be averaged. in each position, pulse 
rate will be counted over 15 s.
Ambulatory BP. The ambulatory BP will be recorded 
using validated (35) oscillometric Mobil-o-Graph 
24-h PWA monitors, which will be programmed to 
obtain readings at 20-min intervals from 08:00 until 
22:00 h and every 60 min from 22:00 until 08:00 h. 
For analysis, daytime is the interval from 10:00 to 
20:00 h, while night-time ranges from midnight to 
06:00 h. These fixed intervals eliminate the transition 
periods in the morning and evening when BP changes 
rapidly, resulting in daytime and night-time BP levels 
that are within 1–2 mmHg of the awake and asleep 
levels (36). if the ambulatory recordings are longer 
than 1 day, only the first 24 h will be analyzed. intra-
individual means of the ambulatory measurements 
will be weighted by the time interval between succes-
sive readings (37).
Central hemodynamic measurements in the supine posi-
tion. During an 8-s period, trained observers will 
record the radial arterial waveform at the dominant 
arm and the carotid waveform by applanation tonom-
etry. They will use a high-fidelity SPC-301 microma-
nometer (Millar instruments, inc., Houston, TX, 
USA) interfaced with a laptop computer running the 
SphygmoCor software (AtCor Medical Pty. Ltd., 
West Ryde, New South Wales, Australia), version 7.1. 
Recordings will be discarded when systolic or dia-
stolic variability of consecutive waveforms exceeds 
5% or when the amplitude of the pulse wave signal 
will be less than 80 mV. The radial and carotid pulse 
wave will be calibrated by the supine brachial BP 
measured immediately before the tonometric record-
ings (38). From the radial signal, the SphygmoCor 
software calculates the aortic pulse wave by means 
of a validated generalized transfer function (39). The 
software returns the central systolic, diastolic and 
pulse pressure, and the pressure at the first and 
second peak or shoulder of the central and radial 
waveforms, from which the systolic augmentation 
index can be derived. The observers will also record 
the carotid and femoral arterial waveforms at the 
right side by applanation tonometry. Using a tape 
measure, they will determine the distance from the 
suprasternal notch to the carotid sampling site (dis-
tance A) and the distance from the suprasternal 
notch to the femoral sampling site (distance B). Pulse 
wave travel distance is (distance B minus distance 
A) 1.12. Pulse transit time will be derived as the 
average of 10 consecutive beats (40). Carotid– 
femoral pulse wave velocity is the ratio of the travel 
distance in meters to transit time in seconds.
Central hemodynamic measurements in ambulatory 
conditions. The Mobil-o-Graph 24-h PWA monitors 
include a high-fidelity pressure sensor (MPX5050, 
Freescale, Tempe, Az, USA) and allow recording of 
the central BP and aortic pulse wave velocity (41–
44). The ARCSolver algorithm, as implemented in 
the monitor, reconstructs the central pulse wave by 
applying a transfer function and incorporates an 
algorithm for checking the quality of the signal (41). 
The recordings are carried out at the brachial artery 
by inflating the cuff slightly above diastolic BP for 
approximately 10 s. The central aortic pressure 
waveform is decomposed into forward and reflected 
waves using an uncalibrated triangular aortic flow 
waveform (41). Pulse wave velocity is estimated 
from the time difference between the derived for-
ward and reflected waves after signal processing 
based on waveform constraint criteria. The model 
used is linear with a continuous parameter space for 
arterial resistance, peripheral resistance and arterial 
compliance. The ARCSolver software computes aor-
tic pulse wave velocity from the reconstructed cen-
tral pulse wave, characteristic impedance and age, 
based on the concept that the ejection work of the 
left ventricle is subject to an optimization principle, 
and assuming a three-element Windkessel model 
(41). The central BP measurements obtained by the 
Mobil-o-Graph 24-h PWA monitor have been 
validated non-invasively (42) and invasively (43), 
and predict cardiovascular events in patients with 
coronary heart disease (44).
Assessment of the nervous system
Heart rate variability. The nurses will record a stan-
dard 12-lead ECG over 16 s by means of the paper-
less Cardiax device (http://www.rdsm.eu/cardiax.
html), interfaced with a computer. Next, they will 
continue recording one peripheral lead with the 
workers in the supine position for 5 min and con-
secutively in free-standing position for another 
5 min. Measurement of heart rate variability in the 
frequency domain provides non-invasive information 
on the role of the autonomic nervous system in the 
control of the cardiovascular system (45). The 
recorded ECGs will be exported using the Cardiax® 
software, version 4.12.5. Next, the exported record-
ings will be analyzed by software, developed in Lab-
ViEW (Laboratory Virtual instrument Engineering 
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Workbench, National instruments, Austin, TX, 
USA) by Beckers and coworkers (46). This software 
performs fast QRS-peak detection in ECG signals. 
After peak detection, the software computes the 
consecutive peak-to-peak intervals, the mean RR 
interval (ms), its total variance or power (ms2), and 
the powers in the low-frequency (0.04–0.15 Hz) 
and high-frequency (0.15–0.40 Hz) bands. The 
low-frequency power predominantly represents 
sympathetic modulation, while the high-frequency 
component of heart rate variability depends on 
vagal activity (45).
Peripheral nerve conduction velocity. Peripheral neu-
ropathy can occur at high exposure to lead. The 
hallmark sign, resulting from damage of the innervat-
ing motor nerves, is wrist drop (47). Nerve conduc-
tion velocity of the motor nerves in this region is a 
subclinical endpoint for peripheral neuropathy (47). 
The study nurses will use a hand-held device and 
accompanying software (Brevio Nerve Conduction 
Monitoring System, NeuMed inc., West Trenton, NJ, 
USA) to stimulate the median nerve at a gradually 
increasing voltage until the maximum compound 
motor action potential of the abductor pollicis brevis 
muscle is reached. They will measure latency (in ms) 
and amplitude (in mV), along with the skin tem-
perature, at the workers’ right and left hands.
Neurocognitive testing. Lead exposure can induce a 
progressive decline of neurocognitive function (48). 
Using a touch screen portable computer, the workers 
will complete the Stroop (49) and Digit-Symbol (50) 
tests, which respectively measure selective attention 
and the speed of scanning and processing visual 
information.
Measurements on blood and urine
Fasting blood and fresh urine samples will be 
obtained at baseline and at the annual follow-up 
visits. Blood samples will be immediately spun and 
divided into aliquots of serum and plasma. Labora-
tories certified by the Clinical Laboratory improve-
ment Amendments of 1988 (CLiA) will perform all 
tests.
Biomarkers of exposure. Blood lead levels will be deter-
mined by inductively coupled plasma mass spec-
trometry (iCP-MS) at an analytical laboratory 
certified for blood lead analysis and in compliance 
with the provisions of the oSHA Lead Standard, 
29CFR 1910.1025 (occupational Safety and Health 
Administration). The analytical laboratory partici-
pates in appropriate blood lead proficiency testing 
programs. Prior to analysis specimens will be digested 
in nitric acid and spiked with an iridium internal 
standard. in addition to blood lead, erythrocyte zinc 
protoporphyrin will be measured, as this biomarker 
is part of the obligatory oSHA panel for monitoring 
lead exposed workers. zinc protoporphyrin does not 
increase above the variations produced by dietary 
variables until blood lead levels exceed 17–20 mg/dl 
(51). Biomarkers of exposure will be measured at 
baseline and at intervals that vary as a function of 
lead exposure intensity as specified by oSHA guide-
lines. Blood lead will be measured more frequently 
within the framework of the regular monitoring of 
lead-exposed workers and is expected to be deter-
mined on at least a quarterly basis.
Other blood tests. Measurements include hemoglobin, 
hematocrit, blood cell counts, iron status (serum iron, 
total iron binding capacity and transferrin satura-
tion), liver function (including g-glutamyltransferase 
as index of alcohol intake), lipid and carbohydrate 
metabolism, renal function, and serum proteins. 
eGFR will be computed from serum creatinine by the 
Modification of Diet in Renal Disease (28) and the 
Chronic Kidney Disease Epidemiology Collaboration 
(29) equations, and from serum cystatin C (27).
Tests on urine. Fresh urine samples will be analyzed 
for specific gravity, pH, glucose, bilirubin, ketones, 
occult blood, protein, nitrite, leukocyte esterase, 
microalbuminuria, uric acid, creatinine and the nico-
tine metabolite cotinine. if the microalbuminuria test 
is positive, a second spot urine sample will be obtained 
to repeat the test within 2–3 weeks.
Database management and statistical analysis
For database management and statistical analysis 
SAS software, version 9.3 (SAS institute inc., Cary, 
NC, USA) will be used.
Data flow and database construction. The Studies 
Coordination Centre will develop electronic case 
report forms (eCRFs) as interactive PDF forms, 
which investigators will complete at the medical 
facilities of the job sites. XML files exported from 
the PDFs will be sent to the Studies Coordination 
Centre. After quality control and addition of the 
codes for symptoms, diseases and concurrent medi-
cations, the XML files will be directly imported 
into the SAS database, using the SAS XML Mapper, 
version 9.3.
Analyses of continuous outcome variables. Mixed mod-
els will be used to study the association between 
changes in BP and renal function and changes in 
blood lead or erythrocyte zinc protoporphyrin. 
Multivariable-adjusted models with BP or changes 
in renal function as dependent variables will 
account for baseline BP or renal function, sex, age, 
follow-up duration, baseline and follow-up body 
mass index, intake of female sex hormones and/or 
non-steroidal anti-inflammatory drugs at baseline 
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and follow-up and three indicator variables coding 
for antihypertensive drug intake (starting or stopping 
treatment between baseline and follow-up and 
remaining on treatment). other covariables of poten-
tial importance are iron status, anemia and lifestyle 
factors such as smoking and drinking. Mixed models 
allow accommodating randomly missing data and 
modeling the individual participant as a random 
effect.
Analyses of categorical outcome variables. To study the 
incidence of categorical endpoints, e.g., hypertension 
or renal dysfunction, we will apply Cox regression 
adjusted for the same covariables as in the continuous 
analyses and with the individual participant modeled 
as a random effect. in these analyses, workers with 
hypertension or renal dysfunction at enrolment will 
be excluded. The added value of various biomarkers, 
including blood lead, to predict study endpoints will 
be assessed using the net reclassification improvement 
and the integrated discrimination improvement (52).
Timelines
SPHERL will run over 4 years and consists of six work 
packages. Milestones are critical steps in the project, 
when a set goal is achieved. Figure 2 is a Gantt chart 
of the project and provides information on work pack-
ages and milestones with associated timelines. if the 
recruitment and retention rate are lower than pro-
jected, the number of sites hosting the study will be 
increased. The primary endpoint is based on 24-h 
ambulatory BP measurement. Ambulatory monitor-
ing has been applied successfully in previous studies 
in populations (53) and workers (54). However, this 
technique causes a slight discomfort, in particular 
during sleep. if this causes a higher than expected 
attrition rate, BP monitoring might be limited to day-
time only. Latency, i.e. the interval between exposure 
and the appearance of clinical measurable effects, is 
an important issue in lead toxicity. if all outcome mea-
sures are unrelated to changing exposure to lead, 
follow-up will be extended. This might be particularly 
applicable for some of the secondary endpoints, for 
which few “longitudinal” data are available to inform 
sample size calculations.
Discussion
SPHERL will assess the effects of low-level lead 
exposure on BP in occupationally exposed workers, 
during a 2-year follow-up study. The study design is 
unique. Foremost, SPHERL is a prospective research 
project including workers who will go from no previ-
ous occupational lead exposure (general population 
blood lead levels) to occupational lead exposure. This 
will capture the low end of the dose–response rela-
tion between cardiovascular, renal and neurological 
function and lead exposure. This information is com-
pletely novel, because the low-level lead exposure 
information is currently only available for the general 
population and study designs in those population 
studies are not as robust as in the SPHERL protocol. 
indeed, BP will be measured peripherally and cen-
trally by 24-h ambulatory monitoring, a bias-free, 
state-of-the-art method (55) implemented in few 
previous studies (6). Measures of BP variability 
derived from the 24-h recordings can be correlated 
with indexes of autonomic nervous function and 
provide information on the overall regulation of the 
cardiovascular system. Furthermore, SPHERL will 
also focus on renal function and the central hemo-
dynamics. As elastin fibers fragment with aging, the 
structural integrity of the arterial wall degrades and 
the BP load is more contained by the non-elastic 
collagen fibers (56). in SPHERL, we will therefore 
measure BP in central elastic arteries as well as the 
1-3 4-6 7-9 10-12 13-15 16-18 19-21 22-24 25-27 28-30 31-33 34-36 37-39 40-42 43-45 46-48
WP1: 
training
WP2: 
initial 
recruitment
WP3: recruitment
WP4: follow-up
WP6: statistical 
analyses 
Months (trimesters)
Milestone 1
Milestone 2
Milestone 4August
2014
August
2015
August
2016
August
2017
Jun/Jul 2018:
Manuscript 
Submission 
Milestone 1: Training completed. Milestone 2: Initial recruitment completed. Milestone 3: Recruitment completed. Milestone 4: Database ready for analyses.  
Milestone 3
WP5: update database and quality control (every three months)
Figure 2. Gantt chart showing work packages and milestones and associated timelines.
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systolic augmentation index, systolic augmentation 
from the central to the peripheral arteries, and aortic 
pulse wave velocity. SPHERL also involves measure-
ment of a large number of other variables that might 
play a role in pathophysiological processes or act as 
confounders in the statistical analysis. The longitudi-
nal design of SPHERL allows the application of 
Bradford–Hill (25) criteria to assess possible causal-
ity between outcome and exposure.
BP and hypertension
in a meta-analysis of 58 518 subjects, the association 
between BP and low-level lead exposure was weak 
with an effect size for a doubling of the blood lead 
concentration of 1 mmHg systolic and 0.6 mmHg 
diastolic (1). To our knowledge, prospective studies 
in populations (4–6) or workers (57) did not show a 
consistent relation between change in BP or inci-
dence of hypertension and the concentration of lead 
in blood (4–6,57) or bone (5,57).
in the Normative Aging Study (5), cross-sectional 
analyses of 519 subjects with no history of definite 
hypertension at baseline and having a representative 
blood lead level of the American population in this 
age range (mean  6.09 mg/dl), revealed positive 
associations between systolic BP and bone lead 
levels. in addition, the risk of developing definite 
hypertension (a BP of at least 160 mmHg systolic or 
95 mmHg diastolic, or use of antihypertensive drugs) 
was associated with the lead concentration in the 
patella (trabecular bone), but not in the tibia (corti-
cal bone) or in the blood (5). in a study by Møller 
& Kristensen conducted in Copenhagen County 
from 1976 until 1987, blood lead fell by 40% in men 
over 11 years and by 30% in women over 5 years 
(4). in 1976, in unadjusted analyses, there was an 
association between systolic BP and blood lead in 
both sexes, but at follow-up, it disappeared in men 
or was inconsistent over time in women (4). in the 
longitudinal (1985–1995) Public Health and Envi-
ronmental Exposure to Cadmium study (PheeCad) 
in Belgium (6), the blood lead concentration among 
728 participants averaged 8.7 mg/dl at baseline and 
decreased by 32% over a median follow-up of 
5.2 years. The study did not show any consistent 
association between the changes in the convention-
ally measured BP or the incidence of hypertension 
with the changes in the blood lead or zinc protopor-
phyrin. The 24-h ambulatory BP, only measured at 
follow-up in 684 participants, neither correlated 
with blood lead nor zinc protoporphyrin at baseline 
or follow-up (6).
in a longitudinal study (1994–1998) of 496 work-
ers, blood lead at baseline averaged 4.6 mg/dl (57) and 
tibia lead at year 3 averaged 14.7 mg/g bone mineral. 
Change in systolic BP during the study was associated 
with lead dose, with an average annual increase of 0.64, 
0.73 and 0.61 mmHg for every standard deviation 
increase in blood lead at baseline, tibia lead at year 3 
or peak past tibia lead, respectively (57). SPHERL is 
specifically designed to expand the data available in 
lead workers. The study is also likely to provide the 
only data available in workers that covers the region 
of the response-exposure relation from no or low lead 
exposure to occupational levels of exposure, thanks to 
the prospective follow-up of new hires.
Renal function
Muntner and colleagues (9) examined the associa-
tion between renal function and blood lead in the 
Third National Health and Nutrition Examination 
Survey (NHANES). Among 4813 hypertensive 
patients, blood lead averaged 4.21 mg/dl and the 
prevalence of elevated serum creatinine and chronic 
kidney disease was 11.5% and 10.0%, respectively. 
Thresholds for serum creatinine varied from 1.2 to 
1.6 mg/dl depending on ethnicity and sex, whereas 
chronic kidney disease was an eGFR below 60 ml/
min/1.73 m2 (9). on the other hand, among 10 398 
normotensive individuals, the blood lead concentra-
tion averaged 3.30 mg/dl, while the prevalence of 
elevated serum creatinine and chronic kidney disease 
were only 1.8% and 1.1%, respectively. in multivar-
iable-adjusted analyses, elevated serum creatinine 
and the prevalence of chronic kidney disease were 
associated with blood lead among hypertensive 
patients, but not among normotensive individuals (9).
The Normative Aging Study investigators pub-
lished a so-called longitudinal assessment of the 
association between renal function and blood lead 
(14). Among 459 men, a 10-fold increase in blood 
lead level predicted an increase in the serum creati-
nine concentration by 80 mg/dl (p  0.005). The asso-
ciation was also significant among men, whose blood 
lead concentration had never exceeded 10 mg/dl. 
However, these analyses were cross-sectional, corre-
lating concurrently measured serum creatinine and 
blood lead in participants with the number of mea-
surements ranging from two to six. Each participant 
was therefore included at least twice in the regression 
models. There was no correlation between changes 
in serum creatinine and blood lead from one visit to 
the next (p  0.11). The age-related increase in serum 
creatinine was earlier and faster in the highest com-
pared with the lowest quartile of the time-weighted 
average of lead exposure (14). inverse associations 
between renal function and the blood lead concen-
tration have also been reported in Belgium (2), 
Sweden (10) and Taiwan (11).
However, the aforementioned studies on the 
association between renal function and lead exposure 
are vulnerable to reverse causality. No study ascer-
tained whether the potentially nephrotoxicity of lead 
impaired renal function or whether renal dysfunction 
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diminished the capacity of the kidney to excrete lead. 
Moreover, hypertension was insufficiently accounted 
for. For instance, it is striking that in Muntner’s study 
(9), the blood lead levels were similar in hypertensive 
patients and normotensive participants, suggesting 
that hypertension rather than lead exposure might 
have been the main factor underlying the worse renal 
function. Along similar lines, comorbidities, such as 
diabetes mellitus (13) or widespread atherosclerosis 
(12) might have contributed to renal dysfunction. 
EPA’s 2006 report (20) and the 2012 National 
Toxicology Program Monograph (19) considered the 
evidence for reverse causality to be insufficient to 
explain the associations between renal outcomes and 
lead exposure. However, both documents did not 
offer definite conclusions.
Function of the nervous system
A meta-analysis on neurobehavioral outcomes by 
Meyer-Baron & Seeber included 22 studies covering 
exposures with blood lead levels below 70 mg/dl (58). 
As a consequence of differences in the test proce-
dures or insufficiently documented test results, only 
12 studies could be retained in the meta-analysis 
(58). For most neurobehavioral tests, the effects sizes 
were qualified as small (58). However, for the Block 
Design test that gives some indication about visu-
ospatial conceptualization, the effect size was equiv-
alent to the loss of function that occurs with 20 years 
of aging (58).
Araki and coauthors reviewed 120 articles on 
peripheral, central and autonomic nervous system 
effects in lead workers (59). They reported that the 
reduction in the peripheral nerve conduction veloc-
ity, together with the effects on the event-related 
potential latency, postural balance and electrocar-
diographic heart rate variability, occurs at a mean 
blood lead concentration of 30–40 mg/dl. The effects 
on the latencies of the short-latency somatosen-
sory, visual and brainstem auditory evoked poten-
tials, as well as the distribution of nerve conduction 
velocities, started at a blood lead concentration of 
40–50 mg/dl (59). A major limitation of these previ-
ous studies (58–60) is that most had a cross-sec-
tional design, that most accounted for a limited 
number of confounders, and that they cannot be 
extrapolated to current levels of exposure in the 
working environment.
Conclusions
SPHERL will provide a unique opportunity to inves-
tigate the effects of lead exposure on BP, cardiovas-
cular regulation, renal function, cognitive function 
and the autonomic nervous system that could not 
be reliably studied from cross-sectional population 
studies or small occupational studies. The results 
might help to define the lead levels associated with 
adverse effects in guidelines worldwide. Elucidation 
of the molecular pathways of lead toxicity is beyond 
the scope of SPHERL. Nevertheless, clinical obser-
vations collected within the current study might 
inform further mechanistic studies to be conducted 
in the laboratory. 
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